Latest Period
Q4 2025
Security Snapshot
Nuvation Bio Inc. - Common Stock (NUVB) Institutional Ownership
CUSIP: 67080N101
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
222
Shares (Excl. Options)
211,332,346
Price
$8.96
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- NUVB on NYSE
- Shares outstanding
- 339,200,672
- Price per share
- $4.53
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 211,332,346
- Total reported value
- $1,893,172,504
- % of total 13F portfolios
- 0.01%
- Share change
- -12,204,164
- Value change
- -$57,998,696
- Number of holders
- 222
- Price from insider filings
- $4.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NUVB - Nuvation Bio Inc. - Common Stock is tracked under CUSIP 67080N101.
- 222 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 222 to 143 between Q4 2025 and Q1 2026.
- Reported value moved from $1,893,172,504 to $429,311,437.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 222 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 67080N101?
CUSIP 67080N101 identifies NUVB - Nuvation Bio Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080N101:
Significant Owners of Nuvation Bio Inc. - Common Stock (NUVB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +11% | $110,306,310 | +$11,583,764 | 50,599,225 | +12% | FMR LLC | 31 Mar 2025 |
| BlackRock, Inc. | 6.4% | +30% | $42,332,244 | +$10,273,842 | 21,708,843 | +32% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 222 institutional investors reported holding 211,332,346 shares of Nuvation Bio Inc. - Common Stock (NUVB). This represents 62% of the company’s total 339,200,672 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Nuvation Bio Inc. - Common Stock (NUVB) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 51,424,981 | +1.7% | 0.02% | $460,767,830 |
| Decheng Capital LLC | 7.7% | 25,954,439 | 0% | 31% | $232,551,773 |
| BlackRock, Inc. | 7.3% | 24,669,776 | +0.27% | 0% | $221,041,196 |
| VANGUARD GROUP INC | 4.6% | 15,555,606 | +0.65% | 0% | $139,378,229 |
| Omega Fund Management, LLC | 2.4% | 8,081,089 | -8.5% | 25% | $72,406,557 |
| Laurion Capital Management LP | 2.3% | 7,852,638 | -19% | 4.8% | $70,359,636 |
| STATE STREET CORP | 1.7% | 5,858,782 | -3.8% | 0% | $52,494,687 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 5,712,296 | -3% | 0% | $51,191,720 |
| TANG CAPITAL MANAGEMENT LLC | 1.1% | 3,857,457 | -8.2% | 1.7% | $34,562,815 |
| ABRAMS CAPITAL MANAGEMENT, L.P. | 1.1% | 3,811,513 | 0% | 0.6% | $34,151,156 |
| BANK OF AMERICA CORP /DE/ | 1.1% | 3,809,425 | +505% | 0% | $34,132,448 |
| Redmile Group, LLC | 0.93% | 3,163,256 | +4.4% | 2.1% | $28,342,774 |
| Nuveen, LLC | 0.84% | 2,852,001 | -38% | 0.01% | $25,553,930 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.8% | 2,708,553 | +852% | 0% | $24,270,000 |
| DIMENSIONAL FUND ADVISORS LP | 0.61% | 2,066,360 | -38% | 0% | $18,514,586 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.59% | 2,016,681 | -1.9% | 0% | $18,069,462 |
| NORTHERN TRUST CORP | 0.57% | 1,921,732 | -9.3% | 0% | $17,218,719 |
| GOLDMAN SACHS GROUP INC | 0.5% | 1,696,013 | +41% | 0% | $15,196,276 |
| AQR CAPITAL MANAGEMENT LLC | 0.49% | 1,669,166 | -18% | 0.01% | $14,955,727 |
| Capricorn Fund Managers Ltd | 0.47% | 1,588,854 | 3.4% | $14,236,132 | |
| Knoll Capital Management, LLC | 0.44% | 1,498,591 | +46% | 6.2% | $13,427,375 |
| Qube Research & Technologies Ltd | 0.38% | 1,280,899 | 0.02% | $11,476,855 | |
| MORGAN STANLEY | 0.38% | 1,276,128 | -3.3% | 0% | $11,434,107 |
| ARMISTICE CAPITAL, LLC | 0.37% | 1,263,737 | -45% | 0.28% | $11,323,084 |
| SymBiosis Capital Partners, LLC | 0.37% | 1,250,000 | 0% | 12% | $11,200,000 |
Institutional Holders of Nuvation Bio Inc. - Common Stock (NUVB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 100,103,472 | $429,311,437 | -$33,567,622 | $4.29 | 143 |
| 2025 Q4 | 211,332,346 | $1,893,172,504 | -$57,998,696 | $8.96 | 222 |
| 2025 Q3 | 220,537,335 | $817,798,856 | -$1,495,817 | $3.70 | 201 |
| 2025 Q2 | 224,729,650 | $439,155,420 | +$34,613,471 | $1.95 | 179 |
| 2025 Q1 | 207,335,118 | $364,911,263 | +$18,852,443 | $1.76 | 159 |
| 2024 Q4 | 197,748,566 | $526,027,669 | +$38,581,638 | $2.66 | 159 |
| 2024 Q3 | 187,137,100 | $428,593,958 | +$73,128,321 | $2.29 | 153 |
| 2024 Q2 | 153,048,262 | $446,948,909 | +$52,594,408 | $2.92 | 146 |
| 2024 Q1 | 134,652,746 | $490,113,918 | +$5,142,866 | $3.64 | 122 |
| 2023 Q4 | 134,270,272 | $202,718,680 | -$2,287,216 | $1.51 | 116 |
| 2023 Q3 | 136,892,011 | $183,439,434 | -$9,239,486 | $1.34 | 122 |
| 2023 Q2 | 139,011,387 | $250,194,724 | +$3,219,600 | $1.80 | 120 |
| 2023 Q1 | 137,479,282 | $228,214,660 | -$4,709,474 | $1.66 | 126 |
| 2022 Q4 | 139,580,600 | $267,992,788 | -$12,224,298 | $1.92 | 123 |
| 2022 Q3 | 141,780,239 | $317,588,133 | -$44,323,294 | $2.24 | 116 |
| 2022 Q2 | 155,298,098 | $503,167,223 | -$21,514,875 | $3.24 | 116 |
| 2022 Q1 | 159,104,350 | $836,898,347 | +$14,198,236 | $5.26 | 112 |
| 2021 Q4 | 155,258,449 | $1,319,350,594 | +$21,011,876 | $8.50 | 103 |
| 2021 Q3 | 151,280,175 | $1,503,381,648 | +$33,688,697 | $9.94 | 97 |
| 2021 Q2 | 147,981,823 | $1,364,632,796 | +$15,849,184 | $9.31 | 97 |
| 2021 Q1 | 145,559,447 | $1,478,100,000 | +$1,473,836,329 | $10.45 | 72 |